NCT06885567View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

August 31, 2028

Conditions
Alzheimer DiseaseAlzheimer' Disease
Interventions
DRUG

BEY2153

Participants administer once daily, PO, 26 weeks

DRUG

Placebo

Participants administer once daily, PO, 26 weeks

Trial Locations (3)

Unknown

Severance Hospital, Seoul

SMG-SNU Boramae Medical Center, Seoul

Yeouido St. Mary's Hospital, Seoul

All Listed Sponsors
lead

BeyondBio Inc.

INDUSTRY